Cipla slashes prices of three anti-cancer drugs: Report

08 Nov 2012 Evaluate

Cipla, country’s largest drug maker has reportedly slashed the prices of three anti-cancer drugs - Erlotinib (ERLOCIP), Docetaxel (DOCETAX) and Capecitabine (CAPEGARD). These drugs are used for the treatment of lung and pancreatic cancer, breast cancer, head and neck cancer, gastric cancer, bladder, colorectal and colon cancers.

The company has reported 61.83% rise in its net profit at Rs 500.01 crore as compared to Rs 308.97 crore for the same quarter in the previous year. Total income from operation of the company has increased by 23.86% at Rs 2191.84 crore for quarter under review as compared to Rs 1769.66 crore for the quarter ended September 30, 2011.

Cipla Share Price

1494.40 -10.65 (-0.71%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×